Surface Oncology is an immuno-oncology company on a mission to break through and deliver transformative outcomes for people with cancer. Its researchers prioritize versatility and use multiple established platforms to characterize new therapeutic antibody candidates. These are designed to activate both innate and adaptive immunity to dramatically improve and lengthen patient responses to cancer immunotherapy. The company has a pipeline of novel immunotherapies and a strategic collaboration with Novartis which includes an exclusive worldwide license to Surfaceâs fully human CD73 antibody NZV930 (formerly SRF373), and an option to license an additional undisclosed next-generation cancer immunotherapy. Surface Oncology is headquartered in Cambridge, Massachusetts.
Source
